NCT01018238View on ClinicalTrials.gov

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
InflammationSystemic Lupus Erythematosus
Interventions
DRUG

NNC 0151-0000-0000

Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)

DRUG

placebo

Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)

Trial Locations (1)

11042-1008

Novo Nordisk Clinical Trial Call Center, Lake Success

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY